India’s Wockhardt Sees Profit Nosedive On The Weight Of Import Bans
This article was originally published in PharmAsia News
Executive Summary
Wockhardt earnings reel from mounting regulatory actions from the U.S., UK and EU. Management pledges restructuring to put the company back on track, but no short-term relief is in sight.